Patents by Inventor Ray O. Bahado-Singh

Ray O. Bahado-Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10835148
    Abstract: Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: November 17, 2020
    Assignee: Bioscreening & Diagnostics LLC
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides
  • Patent number: 10745754
    Abstract: Particular aspects of the invention confirm significant differences in methylation of cytosine bases in many loci throughout the genome in cases of congenital heart defect (CHD) compared to normal cases without CHD. Additional aspects provide novel methods for the prediction of congenital heart defects that can be applied to embryos, fetuses, newborns and different stages of postnatal life including childhood and any time in later postnatal life, is disclosed. The method is applicable not only to deoxyribonucleic acid (DNA) found in body fluids such as blood, urine, sputum, amniotic fluid and other tissues of affected individuals in pre- and post-natal life.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: August 18, 2020
    Assignee: Bioscreening & Diagnostics LLC
    Inventor: Ray O. Bahado-Singh
  • Publication number: 20170166965
    Abstract: Particular aspects of the invention confirm significant differences in methylation of cytosine bases in many loci throughout the genome in cases of congenital heart defect (CHD) compared to normal cases without CHD. Additional aspects provide novel methods for the prediction of congenital heart defects that can be applied to embryos, fetuses, newborns and different stages of postnatal life including childhood and any time in later postnatal life, is disclosed. The method is applicable not only to deoxyribonucleic acid (DNA) found in body fluids such as blood, urine, sputum, amniotic fluid and other tissues of affected individuals in pre- and post-natal life.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 15, 2017
    Inventor: Ray O. Bahado-Singh
  • Publication number: 20170156627
    Abstract: Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 8, 2017
    Applicants: BIOSCREENING AND DIAGNOSTICS LLC, KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides
  • Publication number: 20150087553
    Abstract: The present invention is directed to methods for predicting a pregnant woman's risk of developing early-onset preeclampsia or late-onset preeclampsia. The methods are based on measuring one or more metabolites obtained from a pregnant woman's bodily fluid, such as blood or urine, which were found to be predictive of early-onset preeclampsia and late-onset preeclampsia.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 26, 2015
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides
  • Publication number: 20150080263
    Abstract: The present invention is directed to methods for predicting a pregnant woman's risk of carrying a fetus with Down syndrome (Trisomy 21) or Trisomy 18. The methods are based on measuring one or more metabolites obtained from a pregnant woman's bodily fluid, such as blood or urine, and found to be predictive of Trisomy 21 or Trisomy 18.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 19, 2015
    Inventors: Ray O. Bahado-Singh, Kypros Nicolaides